NASDAQ · ANTX
AN2 Therapeutics, Inc.
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
Loading market information…
NASDAQ · MODD · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Modular Medical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Modular Medical, Inc.’s next earnings report is currently expected on Dec 2, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Modular Medical, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Modular Medical, Inc. is an emerging medical technology company primarily focused on the creation, refinement, and market introduction of insulin pumps. The firm aims to leverage advanced technology to increase the adoption and use of these devices among individuals with diabetes. Its main corporate offices are situated in San Diego, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00-100.0% vs estimate |
| Q3 2025 | Feb 13, 2025 | -$0.13-8.33% vs estimate | $0.00-100.0% vs estimate |
|---|
| Q2 2025 | Nov 14, 2024 | -$0.140.0% vs estimate | $0.00-100.0% vs estimate |
|---|
THE ANALYST VIEW
3 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
$2.48-$0.02 (-0.8%)
Boundless Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.62% below the high.
$3.51+$0.51 (+16.83%)
Hyperion DeFi, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.95% below the high.
$0.81+$0.01 (+1.17%)
iBio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.7% below the high.
$1.30+$0.04 (+3.17%)
Myomo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.22% below the high.
$1.05-$0.01 (-0.94%)
Inspira Technologies OXY B.H.N. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$3.34-$0.04 (-1.09%)
Intensity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.32% below the high.
$0.03-$0.00 (-10.98%)
Iterum Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 97.89% below the high.
